VIP (vasoactive intestinal peptide) specifically regulated Th17 cell function in autoimmune inflammation, suppressing the IL-17-producing cells that drive multiple autoimmune diseases — a targeted anti-autoimmune mechanism.
Key findingVIP suppressed Th17 cell differentiation and IL-17 production in autoimmune inflammation models, specifically targeting the pathogenic Th17 response t
What the researchers found
VIP suppressed Th17 cell differentiation and IL-17 production in autoimmune inflammation models, specifically targeting the pathogenic Th17 response that drives rheumatoid arthritis, EAE (MS model), and other autoimmune diseases — precision anti-autoimmune peptide therapy.
Why it matters
Relevant for neuropeptides, inflammation, immune-function.
How the study worked
animal-study study on neuropeptides, inflammation.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation.
Neuroimmunomodulation, 14(3-4), 134-8
Citation
Leceta, Javier; Gomariz, Rosa P; Martinez, Carmen; Carrión, Mar; Arranz, Alicia; Juarranz, Yasmina. (2007). Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation.. Neuroimmunomodulation, 14(3-4), 134-8.